Compass Pathways CEO Kabir Nath stated at the STAT Summit that the company will go slow before it goes fast ahead of the COMP360 FDA submission to avoid early negative patient or provider experiences.
Agree
Disagree
Overview
Debates
Related claims
Topics
Sources
5
52c7ae14
Psychedelic clinical research & trials
56
claims
·
20
news stories
0
5
52c7ae14
Psilocybin
33
claims
·
4
news stories
0
5
52c7ae14
Psychedelics for depression
23
claims
·
2
news stories
0